Palvella Therapeutics

NAQ:PVLA · US6979471090

BiotechnologySmall

360° View

100

Value83

Price/Sales1

Price/Earnings93

Price/Book9

Dividend Yield—

Growth72

Revenue Growth1

Profit Growth87

Capital Growth30

TSR 52w96

Safety88

Leverage41

Liquidity77

Refinancing77

Combined87

Sentiment79

Analyst Opinions100

Pro Holdings81

Opinion Changes81

Market Pulse5

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Employees34

Websitepalvellatx.com

ISINUS6979471090

Last UpdateApr 2, 2026

Index & Theme

GeneticsDermatologyGenetic DisorderBiotechnologyHealth CareScience and Engineering

Description

Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are…

Analysis

Palvella Therapeutics's 360° View rank of 100 places it among the strongest overall — better than 100% of its true peers.

It's growing solidly (72) and looks cheap versus peers (83). On safety it is very well financed (88), and the market shows strongly positive sentiment (79). Taken together, its Combined rank of 87 reads as among the strongest overall.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Palvella Therapeutics with its peers

Protara Therapeutics

NMQ:TARA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

RAPT Therapeutics

NMQ:RAPT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

PMV Pharmaceuticals

NSQ:PMVP

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Nkarta

NSQ:NKTX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Regenxbio

NSQ:RGNX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Xencor

NMQ:XNCR

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →